Table 4.
Multivariable analysis for significant covariates to predict disease-free survival
| Covariate | HR (95% CI) | p-value |
|---|---|---|
| Response before transplant | ||
|
| ||
| CR 1 | ref | |
| CR 2 | 3.13 (0.79, 12.30) | 0.10 |
| Other | 2.11 (0.60, 7.37) | 0.24 |
|
| ||
| Philadelphia chromosome status | ||
|
| ||
| Negative | ref | |
| Positive | 0.35 (0.12, 1.08) | 0.069 |
|
| ||
| Time from initial diagnosis to transplant | ||
|
| ||
| ≤ median | ref | |
| > median | 0.41 (0.13, 1.34) | 0.14 |
|
| ||
| Age in years | ||
|
| ||
| 18–34 | ref | |
| 35–49 | 0.78 (0.29, 2.08) | 0.61 |
| ≥ 50 | 0.76 (0.21, 2.73) | 0.67 |
|
| ||
| Comorbidity score | ||
|
| ||
| ≤ 3 | ref | |
| > 3 | 0.89 (0.27, 2.91) | 0.85 |
|
| ||
| Non-myeloablative regimen | ||
|
| ||
| No | ref | |
| Yes | 2.65 (1.09, 6.46) | 0.032 |
|
| ||
| Extramedullary disease | ||
|
| ||
| No | ref | |
| Yes | 2.25 (0.71, 7.18) | 0.17 |
Abbreviation: ALL, acute lymphoblastic leukemia; CI, confidence interval; CR1, patients in first complete remission; CR2, patients in second complete remission; HR, hazard ratio; ref, reference group.